Institute of Tropical Medicine Antwerp
Foundation of Public Utility

Evidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy

DSpace/Manakin Repository

Show simple item record Mooij, P. en_US Bogers, W. M. en_US Oostermeijer, H. en_US Koornstra, W. en_US ten Haaft, P. J. en_US Verstrepen, B. E. en_US Van der Auwera, G. en_US Heeney, J. L. en_US 2007-12-06T14:47:37Z 2007-12-06T14:47:37Z 2000 en_US
dc.identifier.issn 0022-538X en_US
dc.identifier.other ITG-M7A en_US
dc.identifier.other MICRO en_US
dc.identifier.other U-VIROL en_US
dc.identifier.other JIF en_US
dc.identifier.other ABSTRACT en_US
dc.description.abstract Current strategies in human immunodeficiency virus type 1 (HIV-1) vaccine development are often based on the production of different vaccine antigens according to particular genetic clades of HIV-1 variants. To determine if virus virulence or genetic distance had a greater impact on HIV-1 vaccine efficacy, we designed a series of heterologous chimeric simian/human immunodeficiency virus (SHIV) challenge experiments in HIV-1 subunit-vaccinated rhesus macaques. Of a total of 22 animals, 10 nonimmunized animals served as controls; the remainder were vaccinated with the CCR5 binding envelope of HIV-1(W6.1D). In the first study, heterologous challenge included two nonpathogenic SHIV chimeras encoding the envelopes of the divergent clade B HIV-1(han2) and HIV-1(sf13) strains. In the second study, all immunized animals were rechallenged with SHIV(89. 6p), a virus closely related to the vaccine strain but highly virulent. Protection from either of the divergent SHIV(sf13) or SHIV(han2) challenges was demonstrated in the majority of the vaccinated animals. In contrast, upon challenge with the more related but virulent SHIV(89.6p), protection was achieved in only one of the previously protected vaccinees. A secondary but beneficial effect of immunization on virus load and CD4(+) T-cell counts was observed despite failure to protect from infection. In addition to revealing different levels of protective immunity, these results suggest the importance of developing vaccine strategies capable of protecting from particularly virulent variants of HIV-1. en_US
dc.language English en_US
dc.subject Virology en_US
dc.subject HIV en_US
dc.subject Vaccine development en_US
dc.subject Virulence en_US
dc.title Evidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy en_US
dc.type Article en_US
dc.citation.jtitle Journal of Virology en_US
dc.citation.volume 74 en_US
dc.citation.pages 4017-4027 en_US
dc.citation.jabbreviation J Virol en_US

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record